BioSpace News Archive

There is a new animal hospital in 4S Ranch located in 4S Commons.

Median Technologies, The Imaging Phenomics Company® (Paris: ALMDT), announced today preliminary and unaudited financial results for the first half of 2019.

Luminex Corporation (NASDAQ: LMNX) today announced that it plans to report results for the second quarter ended June 30, 2019 on Wednesday, July 31, 2019.

The Supreme Cannabis Company, Inc. (“Supreme Cannabis” or the “Company”) (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) and Blissco Cannabis Corp. (“Blissco”) (CSE: BLIS) (OTCQB: HSTRF) (FRA: GQ4B:GR) are pleased to announce that the Supreme Court of British Columbia has issued a final order (the “Final Order”) approving the previously announced plan of arrangement (the “Arrangement”) between Supreme Cannabis and Blissco.

Horizon Therapeutics plc (Nasdaq: HZNP) (“Horizon”) today announced that Horizon Pharma USA, Inc., its wholly-owned subsidiary, has priced its offering of $600 million aggregate principal amount of 5.5% senior notes due 2027.

Endo International plc (NASDAQ: ENDP) will announce its second-quarter 2019 financial results on August 6, 2019 and members of its senior management team will host a conference call and webcast at 7:30 a.m. ET before the U.S. financial markets open.

There has been a lot of discussions this week about political alignment at the Council of the Federation, but we’re pleased to see that Premiers are agreeing on one of the most important issues facing this country: the state of our health care system.

More than a year after becoming one of the first medical institutions nationally to complete a revolutionary gene replacement surgery to restore vision in patients with retinal degeneration, surgeons at The Vision Center at Children’s Hospital Los Angeles have successfully completed the procedure on an additional 13 patients.

FUJIFILM Corporation (President: Kenji Sukeno; Fujifilm) and Axcelead Drug Discovery Partners Inc. (President: Yoshinori Ikeura; Axcelead) announced a collaboration to provide customers with a human induced pluripotent stem cell (iPSC)-based integrated platform for drug discovery solutions

The Asthma and Allergy Foundation of America addresses concerns regarding the Final Evidence Report assessing the clinical effectiveness and value of treatments for peanut allergy released by the Institute for Clinical and Economic Review (ICER) on July 10, 2019.